Generic Medicine Info
Indications and Dosage
Adult: 25-100 mg daily in divided doses depending upon clinical response.
Child: ≥ 12 years Same as adult dose.

Motion sickness
Adult: 25-50 mg 1 hour before travel, repeat every 24 hours if necessary.
Child: 2-6 years 6.25 mg once daily; 6-12 years 12.5 mg once daily; >12 years Same as adult dose. All doses to be taken 1 hour before travel, repeat every 24 hours if necessary.
Special Patient Group

In an in-vitro metabolic study, CYP2D6 was noted to be the dominant enzyme for the metabolism of meclozine. FDA drug label states that large inter-individual variability in meclozine exposure may occur in patients with CYP2D6 phenotypes, thus resulting to poor, intermediate, extensive or ultra-rapid metabolism. Monitoring for adverse reactions and clinical effects is recommended in these patients.
May be taken with or without food.
Special Precautions
Patients with asthma, narrow-angle glaucoma, prostatic hyperplasia, bladder neck obstruction, urinary stricture, pyloric or duodenal obstruction. Patients with CYP2D6 polymorphism. Renal and hepatic impairment. Children and elderly. Pregnancy and lactation.
Adverse Reactions
Significant: Drowsiness.
Eye disorders: Rarely, blurred vision.
Gastrointestinal disorders: Dry mouth, vomiting.
General disorders and administration site conditions: Fatigue.
Immune system disorders: Anaphylactic reaction.
Nervous system disorders: Headache.
Patient Counseling Information
This drug may cause drowsiness, if affected, do not drive or operate machinery.
Drug Interactions
May increase CNS depression with tranquilizers and sedatives.
Food Interaction
May enhance CNS depressant effect with alcohol.
Description: Meclozine blocks vasodepressor response to histamine and has a slight blocking action against acetylcholine. It decreases excitability of the middle ear labyrinth and blocks conduction in the middle ear vestibular-cerebellar pathways.
Synonym: Meclizine
Onset: Approx 1 hour.
Duration: Approx 24 hours.
Absorption: Time to peak plasma concentration: Approx 3 hours.
Distribution: Volume of distribution: 7 L/kg.
Metabolism: Metabolised in the liver to norchlorcyclizine.
Excretion: Via urine and faeces as unchanged drug and metabolites. Elimination half-life: Approx 5-6 hours.
Chemical Structure

Chemical Structure Image

Source: National Center for Biotechnology Information. PubChem Database. Meclizine, CID=4034, (accessed on Jan. 22, 2020)

Store between 20-25°C. Protect from light.
MIMS Class
Antiemetics / Antivertigo Drugs
ATC Classification
R06AE05 - meclozine ; Belongs to the class of piperazine derivatives used as systemic antihistamines.
Annotation of FDA Label for Meclizine and CYP2D6. Pharmacogenomics Knowledgebase (PharmGKB). Accessed 18/10/2019.

Anon. Meclozine Hydrochloride. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. Accessed 18/10/2019.

Antivert (Casper Pharma LLC). U.S. FDA. Accessed 18/10/2019.

Bonamine Chewable Tablet (Interphil Laboratories Inc.). MIMS Philippines. Accessed 18/10/2019.

Buckingham R (ed). Meclizine. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. Accessed 18/10/2019.

McEvoy GK, Snow EK, Miller J et al (eds). Meclizine Hydrochloride. AHFS Drug Information (AHFS DI) [online]. American Society of Health-System Pharmacists (ASHP). Accessed 23/11/2015.

Meclizine Hydrochloride Tablet (Amneal Pharmaceuticals LLC). DailyMed. Source: U.S. National Library of Medicine. Accessed 18/10/2019.

Meclizine Hydrochloride Tablet (Epic Pharma, LLC). DailyMed. Source: U.S. National Library of Medicine. Accessed 23/11/2015.

Rugby Travel Sickness Tablet, Chewable (Rugby Laboratories). DailyMed. Source: U.S. National Library of Medicine. Accessed 23/11/2015.

Sea-Legs Tablet (Seton Products Limited). MHRA. Accessed 23/11/2015.

Sea-Legs Tablets (G R Lane Health Products Ltd.). MHRA. Accessed 22/10/2019.

Disclaimer: This information is independently developed by MIMS based on Meclozine from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 MIMS. All rights reserved. Powered by
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in